1. Introduction
Raynaud’s phenomenon (RP) is a chronic vasospastic condition affecting the extremities and is characterized by a triad of pallor, bluish discoloration (cyanosis), and redness. It occurs due to blood vessel constriction in response to cold exposure or emotional stress and can sometimes extend to the lips, earlobes, nipples, and nose tip [
1]. RP triggers a distinctive sequence of color changes in the digits—pallor resulting from vasoconstriction, bluish discoloration due to diminished oxygenated blood flow, and erythema upon reperfusion and hyperemia. The prolonged state of diminished oxygen supply leads to gangrene, ulcers, and ultimately death of tissues [
1,
2]. RP can be classified as either primary/idiopathic, with no known cause, or secondary, linked to conditions such as autoimmune disorders such as systemic sclerosis, vascular diseases, and neurological disorders. The reported prevalence of RP ranges from 2.1% to 22.4%, varying across studies due to factors such as geographic location, ethnicity, and differences in diagnostic criteria [
3]. The precise origin of RP is unknown, but genetic and hormonal factors—particularly estrogen—may play a role and may explain the increased prevalence of RP in females compared to males [
1]. Its pathogenesis arises from a complex interaction among the vascular wall, nerves, hormones, and humoral factors, resulting in an imbalance between vasoconstriction and vasodilation [
4]. There is no known cure for RP, but management involves pharmacological and nonpharmacological modalities. Nonpharmacological management is recommended for all patients and mainly involves avoiding triggers, i.e., cold exposure and stressors. Pharmacological management includes the use of calcium channel blockers (first-line therapy). The dihydropyridine class of calcium antagonists (e.g., nifedipine, amlodipine) is preferred for use in RP, with nifedipine as the most employed as the drug of choice [
5]. Angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists, and selective serotonin reuptake inhibitors are additionally utilized in the treatment of uncomplicated RP [
1]. In cases of complicated RP, oral PDE5 (phosphodiesterase-5) inhibitors and IV prostanoids are employed. Endothelin-1 receptor antagonists such as bosentan, botulinum toxin (Botox), and surgical therapy like sympathectomy are other management options used in severe and refractory cases of RP [
4].
The role of PDE5 inhibitors in RP has been increasingly evaluated, with results from a meta-analysis showing a moderate but significant improvement in RP symptoms [
6]. Tadalafil (TDL), a selective PDE-5 inhibitor, increases cGMP levels, leading to vasodilation and smooth muscle relaxation. It is used to treat erectile dysfunction [
7], pulmonary arterial hypertension [
8], and benign prostatic hyperplasia [
9]. A clinical trial for the use of TDL in RP was undertaken with promising results albeit a small sample size [
10]. TDL has also been evaluated as an add-on therapy in secondary resistant RP and was observed to improve the symptoms of RP, preventing and healing digital ulcers and enhancing overall quality of life [
11].
TDL belongs to BCS class II drugs with low water solubility (3.2 µg/mL), leading to variable absorption and an undetermined absolute bioavailability [
12]. TDL has a longer half-life (15–17 h), higher selectivity for PDE-5, and lower affinity for PDE-6, which reduces the risk of visual side effects commonly associated with other PDE-5 inhibitors [
13]. It also has the slowest absorption rate among PDE-5 inhibitors, which limits the effectiveness of its oral formulation [
13]. Its optimum log
p value of 2.89, relatively low molecular weight (389.4 g/mol), and low dose make TDL a potential candidate for alternative drug delivery methods, such as transdermal administration [
14].
Transdermal and dermal delivery systems are thought to be an appealing alternative route for drug administration, offering both local and/or systemic activity, in comparison to oral and parenteral delivery systems [
15]. The transdermal delivery system (TDDS) is advantageous as it bypasses hepatic first-pass metabolism, providing a constant plasma drug concentration, increasing bioavailability, reducing dosing frequency, and decreasing systemic side effects [
16]. Moreover, it promotes tolerability and compliance by being non-invasive, painless, easy to administer, minimizing stomach irritation, overcoming unappealing taste, and providing a good option for individuals with dysphagia [
17]. The non-viable uppermost skin layer, known as the stratum corneum, acts as a physiological barrier, which generally restricts drug absorption and permeability in topical and transdermal delivery systems [
18]. As the skin’s natural barrier properties pose challenges for TDDS, efforts to enhance transdermal delivery are ongoing, with current methods focused on increasing penetration into the skin layers through the use of penetration enhancers, such as chemical agents, techniques like iontophoresis, sonophoresis, electroporation, microneedles, thermophoresis, or thermal ablation, and drug delivery carriers like nanoparticles, albeit with certain drawbacks [
19]. These limitations include constraints in drug applicability, potential for skin irritation, limited skin penetration depth, risk of infection, safety concerns, and the need for specialized equipment.
Transdermal delivery of TDL has been explored in various studies. In one attempt, TDL-loaded nanostructured lipid carriers have been fabricated to enhance its skin permeability upon the inclusion of ethyl alcohol and limonene [
20]. However, the inclusion of ethyl alcohol in transdermal formulation has the potential to induce skin dryness, irritation, or contact dermatitis, both of which can aggravate the condition of RP [
21]. In another attempt, formulation using Carbopol 940 gel with hydroxypropyl-β-cyclodextrin (HPβCD) and oleic acid confirmed enhanced TDL solubility and permeability [
13]. Though the inclusion of HPβCD in transdermal formulations improves solubility and reduces irritation, its inherent hydrophilicity limits its permeability, often necessitating additional enhancers [
22]. It also presents challenges such as drug retention and higher cost. Recently, a transdermal formulation of TDL was developed and evaluated using Strat-M
® membrane [
23]. The formulation, which utilized hexadecyltrimethylammonium bromide (HDTMA-Br) with dipropylene glycol, showed good skin permeability and remained stable over 12 months. However, HDTMA-Br is not currently approved for transdermal pharmaceutical products by major regulatory agencies due to safety and irritation concerns in human use. On the other hand, nanoemulsion-based oral jellies loaded with TDL demonstrated improved bioavailability compared to the free form of TDL [
24]. However, the observed maximum plasma concentration (C
max) and area under the curve (AUC) were relatively low, suggesting relatively poor absorption through the oral route. A recent study optimized a TDL nano-ointment with a particle size of 208 nm, polydispersity index (PDI) of 0.404, and zeta potential of 31.0 mV, indicating good stability and uniform dispersion [
25]. In vitro and ex vivo studies demonstrated that the nano-ointment provided sustained, controlled release of TDL following zero-order kinetics, with better drug permeation correlation than the TDL cream. Although the formulation was proposed for RP management, no pharmacodynamic or pharmacokinetic studies were conducted to substantiate its in vivo therapeutic efficacy. Based on all these observations, the development of a new transdermal formulation of TDL is warranted, with a focus on ensuring safety and non-irritancy for use in patients with RP.
Nanovesicles demonstrate significant promise in TDDS by virtue of their unique properties like small size, high surface area to volume ratio, potential to encapsulate both hydrophilic and lipophilic drugs, skin permeation without significantly changing the skin’s physiological and functional characteristics [
26]. Nanovesicles are often favored over nanoparticles in TDDS due to their superior skin absorption, compatibility with biological systems, adaptability, increased stability, extended drug release, and ability to target specific areas. Drug encapsulation in lipid nanocarriers presents a viable strategy for effective delivery, with predictable characteristics that improve bioavailability and reduce undesirable side effects [
27]. Among various lipid-based nanosystems, nanoemulsions are favored for transdermal drug delivery because of their unique characteristics and advantages over other lipid nanovesicles [
28]. Nanoemulsions can enhance skin penetration of drugs by reducing the barrier function of the skin, improving drug partitioning into the skin, and enhancing drug retention in the skin. Thus, nanoemulsions can be considered an ideal platform for transdermal therapy due to their advantages, such as prolonged drug release, enhanced stability, versatility, biocompatibility, and ease of scale-up [
29].
Nanoemulgel is an advanced drug delivery system that combines nanoemulsion droplets within an aqueous gel matrix, creating a stable, non-greasy, and thixotropic formulation. This system enhances drug penetration, permeability, and absorption, providing prolonged drug release, and improved stability making it ideal for transdermal drug delivery [
30]. Furthermore, gel formulations are convenient to apply, rarely cause skin irritation, and thus enhance patient compliance [
31].
Even though TDL has been recommended as an oral add-on therapy for RP, research on its nanoformulation for transdermal delivery remains limited, highlighting the need for further studies. Therefore, the current research aimed to develop and evaluate a TDL-loaded nanoemulgel for transdermal delivery to enhance bioavailability and assess its therapeutic efficacy in managing RP using a cold-induced vasoconstriction rat model. The selected TDL-loaded nanoemulgel was evaluated for TDL release, transdermal permeation, and in vivo efficacy in the rat model.
2. Materials and Methods
2.1. Materials
TDL was donated by Julphar Pharmaceuticals, Ras Al Khaimah, UAE. Cremophor RH 40 was purchased from Sigma Aldrich (St. Louis, MO, USA), and Carbopol 934 was procured from SRL CHEM (Mumbai, India). Diethylene glycol monoethyl ether (Transcutol/Carbitol) 98% was obtained from Loba Chemie (Mumbai, India). Cinnamon oil was procured from AVD Organics (Mumbai, India). All other chemicals, including ketamine and xylazine used for the animal studies, were employed in their received form and were of reagent grade or higher quality.
2.2. HPLC Determination of Tadalafil
Quantification of TDL was carried out in an HPLC system (Shimadzu, Kyoto, Japan) with an LC-20AD pump, DGU-20A 3 degasser, SPD-20A UV-VIS detector, and a Restex Force C18 column (5 μm, 150 × 4.6 mm). The mobile phase consisted of acetonitrile and water in a 45%:55% (v/v) ratio with 0.1% trifluoracetic acid. The flow rate of the mobile phase was fixed at 1 mL/min, and the temperature of the column was maintained at 40 °C. After injecting 20 µL samples, the chromatogram was recorded (wavelength of 285 nm). For TDL concentration analysis, plasma was subjected to HPLC after protein precipitation with 100 µL of 1N HCl and 2 mL of diethyl ether, followed by vortexing for 10 min. Subsequently, the samples were centrifuged at 4000 rpm for 15 min, after which the supernatant was collected, filtered, and dried. The residue obtained was then mixed with the mobile phase, filtered (0.45 µm syringe filter), and further injected into the HPLC column. The drug level of TDL between 0.0625–12 µg/mL showed good linearity (R2 = 0.9989).
2.3. Screening of Oil
The equilibrium solubility of TDL in selected oils was measured [
32] by adding an excess quantity of the drug to 1 mL of oils (Miglyol
® 812 N, Miglyol
® 840, Miglyol
® 829, triacetin, isopropyl myristate, castor oil, oleic acid, cinnamon oil, N-methyl pyrrolidone) separately in 1.5 mL stoppered glass vials and mixed by a vortex mixer. Samples were further placed at room temperature (25 ± 1 °C) on a shaker (Incu-Shaker, Benchmark Scientific, Edison, NJ, USA) at 180 rpm for 72 h. The mixture was further centrifuged for 15 min at 3000 rpm. The upper supernatant was removed, and the amount of drug was determined using UV analyzer (Jenway, Staffs, UK) at a lambda max of 284 nm. The data presented in
Table 1 are the mean values and standard deviations (SDs) for each oil sample, based on three replicates.
2.4. Screening of Surfactants and Cosurfactants
The solubility screening of TDL in various surfactants (Tween 80, Span 80, Cremophor RH 40, PEG-400, propylene glycol, isopropyl alcohol, and Transcutol) was performed following the same procedure as the oil screening. The results presented in the article are the mean values and standard deviations (SDs) for surfactant and cosurfactant samples, based on three replicates.
2.5. Construction of Pseudoternary Phase Diagram
To determine the nanoemulsion area, the pseudoternary phase diagram was generated by systematically altering the surfactant, cosurfactant, oil, and aqueous phase ratios. The surfactant and cosurfactant were blended in various weight ratios (3:1, 2:1, 1:1, 1:0, 1:0.25, 1:0.5, and 1:0.7) to create different Smix combinations. Oil was then incorporated into the Smix system and the aqueous titration technique was utilized to create the phase diagram utilizing a vortex mixer (Model: REMI CM-101, Mumbai, India) at 25 ± 1 °C. To ensure comprehensive coverage of possible formulations, the oil-to-water (o/w) ratios were varied across a wide range (9:1, 8:2, 7:3, 6:4, 5:5). The resulting mixtures were visually assessed to identify the nanoemulsion region, characterized by clear, transparent, and easily flowable formulations. Mixtures that appeared turbid or showed phase separation were considered outside the nanoemulsion region. The final pseudoternary phase diagram was plotted with three axes representing the Smix system, aqueous phase, and oil phase. This diagram provided a visual representation of the regions where stable nanoemulsions formed, offering critical insights into the optimal formulation parameters for transdermal delivery systems.
2.6. Preparation of Tadalafil-Loaded Nanoemulsion
The schematic representation of nanoemulsion preparation is shown in
Figure 1. TDL was first dissolved in the selected oil phase (cinnamon oil) by gentle mixing. Deionized water was then added as the aqueous phase, followed by the incorporation of Smix (Cremophor 40 and Transcutol) in a 1:0.7
v/
v ratio. The composition was blended using a cyclomixer (REMI CM-101, Mumbai, India) for 5 min to ensure uniformity. Later, the mixture was then subjected to ultrasonication in a bath sonicator (Model: Nickel-Electro, SW3H, Basel, Switzerland) at room temperature (25 ± 1 °C) for 5 min at a frequency of 20 kHz to form nanodroplets and achieve a stable nanoemulsion. All experiments were performed in triplicate, and the resulting data are presented as the mean values with standard deviations (SDs).
2.7. Characterization of TDL-Loaded Nanoemulsion
2.7.1. Drug Content
A precisely measured 1 mL of TDL-loaded nanoemulsion was placed in a polypropylene centrifuge tube, followed by the gradual addition of the mobile phase. The mixture was agitated for 1 h using a mechanical shaker (Incu-Shaker, Benchmark Scientific, Edison, NJ, USA) to achieve a uniform solution. It was then centrifuged (MiniSpin, Eppendorf, Germany) at 4280× g for 10 min. The resultant supernatant (1 mL) was filtered with syringe filter (pore size, 0.22 µm). The drug content was determined by HPLC after appropriate dilution. All results are expressed as the mean ± standard deviation (n = 3) for each sample.
2.7.2. Percentage Transmittance and pH
The transmittance of nanoemulsions was measured using a UV spectrophotometer (Jenway, Staffs, UK). The instrument was calibrated by setting the transmittance to 100% with a transparent cuvette containing double-distilled water as a blank at 400 nm. Nanoemulsion samples were then placed in the cuvette, and their percentage transmittance was recorded. The formulations (S1–S7) were tested for pH at 25 ± 1 °C with the help of pH meter (Jen-way 3510, Staffs, UK). All the experiments were conducted in triplicate and the data generated were presented as the mean values and SDs.
2.7.3. Dilution Potential
The dilution test was conducted to examine the potential phase inversion of the optimized nanoemulsions. To assess the dilution potential, nanoemulsion (1 mL) was diluted tenfold with deionized water in a test tube, and no occurrence of phase separation was observed. Data are reported as the mean ± SD. from three independent experiments.
2.7.4. Droplet Size and Zeta Potential
The average particle size along with the PDI, as well as zeta potential of nanoemulsion was evaluated by Horiba Zetasizer (model, SZ-100, Kyoto, Japan). Approximately 2 mL of test samples were placed in the chamber and analysed for particle size and zeta potential using Horiba SZ-100 software (Z-type, version 2.20, Kyoto, Japan). All experiments were carried out in triplicate, and the resulting data are presented as the mean values with standard deviations (SD).
2.7.5. Viscosity
The viscosity of the selected nanoemulsions (S1–S7) was measured at various angular velocities at 25 °C using an Atago viscometer (Visco-895, Tokyo, Japan) [
33]. Data are expressed as the mean ± SD from triplicate experiments.
2.7.6. Thermodynamic Stability Studies
The purpose of this study was to evaluate the physical stability of selected formulations through various tests. In the heating–cooling cycle, the nanoemulsions underwent six cycles between 4 °C and 45 °C, with a storage period of at least 48 h at each temperature, to evaluate their stability under extreme temperature fluctuations, using refrigerator (LG Electronics, New Delhi, India) and Hot air oven (SCT-Convect-1, Sci-Chem, Mumbai, India). The centrifugation test involved spinning the formulations at 3500 rpm for 30 min to assess for any phase separation, performed with a high-speed centrifuge (MiniSpin, Eppendorf, Hamburg, Germany). Additionally, a freeze–thaw cycle test was performed with three cycles between −21 °C and 25 °C, where the formulations were placed at a particular temperature for at least 48 h to observe any signs of instability, using a deep freezer (Forma, Thermo Fisher Scientific, Waltham, MA, USA) and at room temperature. All the experiments were conducted in triplicate and the data generated were presented as the mean values and SDs.
2.7.7. Fourier-Transform Infrared (FTIR) Spectroscopy
The potential drug–formulation component interactions and the stability of TDL in formulation ingredients were assessed using FTIR spectroscopy. IR spectra of TDL, a blank nanoemulsion, and a drug-loaded nanoemulsion were collected for samples stored for 30 days at 25 ± 0.2 °C and 75% ± 5% RH [
19]. After the storage period, the samples were analyzed using a Shimadzu FTIR spectrometer (IRXross, Shimadzu, Kyoto, Japan) equipped with a diamond attenuated total reflectance accessory. This facilitates direct measurement by pressing the sample against a diamond prism and accommodates various sample types. Scanning was performed in the range of 145 to 4000 cm
−1, with ~25 scans/sample and 2 cm
−1 resolution. The spectra of TDL, the blank nanoemulsion, and the drug-loaded nanoemulsion samples were compared to identify any variations in the characteristic peaks of the drug, indicating potential interactions.
2.7.8. Transmission Electron Microscopy (TEM)
The morphology of the prepared nanoemulsion was analyzed with TEM (TFS TALOS F200X, Thermo Fisher Scientific, Waltham, MA, USA) operated at 200 kV [
34]. Imaging was carried out by placing the sample directly on the carbon-coated TEM grid and incubating it for 10 s before washing for 25 times and drying it at room temperature (25 ± 2 °C).
2.7.9. In Vitro Release
The release of TDL from nanoemulsion was evaluated using a vertical Franz diffusion cell (Orchid Scientific, Nashik, India), as suggested for the release testing of topical preparations [
35]. The release barrier was a cellophane dialyzing membrane (MWCO 12–14 kDa), which had been soaked in deionized water overnight. The membrane was positioned between the upper and lower chambers, with an active drug release area of 0.64 cm
2. An accurately weighed amount (1 mL) of selected nanoemulsions (contains 2 mg of TDL) was kept in the top chamber [
36]. The release medium, consisting of phosphate buffer (pH 7.4) with 0.2%
w/
v Transcutol, was included in the receiver compartment to retain sink conditions. The system was maintained at 37 ± 0.5 °C and agitated at 100 rpm. At particular time intervals, aliquots were collected and replaced with fresh solvent. The collected samples were further filtered, diluted with the mobile phase, and analyzed for TDL by the previously described HPLC method. The release kinetics and mechanism were assessed by calculating the correlation coefficient (r
2) using various mathematical models described in the literature [
37]. All experiments were carried out in triplicate, and the resulting data are presented as the mean values with standard deviations (SDs).
2.8. Preparation of Tadalafil-Loaded Nanoemulgel
The optimized TDL-loaded nanoemulsion (S3) was converted into a gel formulation to enhance skin penetration and prolong drug release. The gel base was formulated by dispersing 1 g of Carbopol 934 in water to achieve a 1% w/w concentration, followed by soaking for 12 h to allow complete hydration of the polymer. A 10 g portion of the hydrated Carbopol was then neutralized with 2% triethanolamine to form a viscous gel base. The optimized nanoemulgel was prepared by incorporating 5 mL of the nanoemulsion, equivalent to 20 mg of TDL, into 5 g of the neutralized Carbopol gel. The final formulation was designed such that 1 g of the gel contained 2 mg of TDL, making it suitable for topical application.
2.9. Characterization of Nanoemulgel
The TDL-loaded nanoemulgel was visually assessed for color, uniformity, phase separation, pH, and viscosity. The spreadability of the prepared nanoemulgel was tested by placing 1 g of the gel on a glass plate (5 cm
2 area), covering it with another glass plate, allowing it to spread for 5 min and the diameter was recorded [
38].
2.10. Permeation Studies
The ex-vivo skin permeation ability of developed TDL-loaded nanoemulgel was evaluated using excised Wistar rat skin and the standard Franz diffusion technique [
39]. The diffusion cell has an active permeation area of ~0.64 cm
2, with a receiver cell volume of 5 mL, maintained at 37 ± 1 °C. Skin membranes were prepared by removing the hair, excising the dorsal skin, and removing the visceral tissue. The excised skin was stored at −20 °C until experimentation. Phosphate buffer solution (pH 7.4) and ethanol in a 50:50 ratio was used as a receptor medium to keep sink conditions. The receptor medium was stirred continuously at 150 rpm using Teflon coated magnetic bead in a magnetic stirrer. The rat skin was positioned on the Franz cells with the dermis side facing the receptor compartment, and the TDL gel (equivalent to 2 mg of drug) was placed on the donor compartment. Samples of the receptor fluid were taken at various time points, filtered, and checked for TDL content using HPLC. All experiments were conducted in triplicate, and the data are reported as the mean ± standard deviation (SD).
2.11. Pharmacodynamic Studies
The animal experiment procedure was approved by the Animal Ethics Committee (AEC) of Ras Al Khaimah Medical and Health Sciences University (AEC-RAKMHSU-PG-C-02-2023-2024). Adult female Wistar rats (12 weeks old; 200–250 g) were housed under controlled conditions at 22 ± 2 °C and 40–60% humidity, with a 12-h light/dark cycle, and were provided food and water ad libitum. The rats were randomly assigned into four groups (6 rats per group) as follows: Group I (n = 6): Normal control group (baseline; neither subjected to cold induction nor drug application). Group II (n = 6): Model untreated group (subjected to cold-induced vasoconstriction only). Group III (n = 6): Standard group (treated with a standard formulation: 0.2%
w/
w nitroglycerin topical ointment). Group IV (n = 6): TDL-treated group (received TDL-loaded nanoemulgel). The rats were placed in a fixator with their tails exposed, and TDL-loaded nanoemulgel (gel containing 2 mg of drug) was applied to the tail at room temperature (24 ± 2 °C). Following the application, the tails of the rats (excluding the normal control group) were submerged in a 10 °C water bath for 5 min to induce in-vivo vasoconstriction. Regional blood flow in the caudal arterial cortex was measured using infrared thermal imaging (Ti120, Hanmatek, Shenzhen, China) at 24 °C and again at 10 °C to confirm vasoconstriction [
40,
41].
2.12. Pharmacokinetic Studies
The adult female Wistar rats (200–250 g) utilized in the in vivo pharmacokinetic investigation were kept at room temperature (22 ± 2 °C) with a 12-h light/dark cycle. The rats were provided food and water and observed for one day. Two groups of six rats each (n = 6) were randomly selected from among all the animals. Animals were anesthetized by intraperitoneal administration of ketamine (40 mg/kg) and xylazine (5 mg/kg). In Group 1 (n = 6), the dorsal area hair was removed, and 1 g of the optimized TDL nanoemulgel (containing 2 mg of TDL) was applied uniformly to the skin. In Group 2 (n = 6), TDL suspension in 0.5% HPMC solution (1 mL, containing 2 mg of TDL) was administered orally using an intragastric gavage. The dose of 2 mg of TDL was calculated based on the human equivalent dose (10 mg), using a standard body surface area conversion equation described in the literature [
42]. Blood samples (~200 µL) were withdrawn from the retro-orbital plexus at predefined time points. Each sample was transferred to dry heparinized tubes, and 1 mL of normal saline was administered via intragastric gavage after each sample collection to prevent dehydration. Plasma samples were treated with 1N HCl and 2 mL diethyl ether, then vortexed for 10 min to precipitate proteins. After centrifuging (4000 rpm) for 15 min, the top layer was removed, filtered, and dried. A 45:55 (
v/
v) ratio of acetonitrile: water (contains 0.1% trifluoroacetic acid) was used to dissolve the residue, and HPLC was used for analysis. Various pharmacokinetic parameters were determined using non-compartmental analysis.
2.13. Skin Irritation Test
The backs of two groups of six adult female Wistar rats (200–250 g) were shaved 24 h before the irritation study. Blank nanoemulgel (without TDL) was applied to the control group (n = 6), while TDL-loaded nanoemulgel was applied to the test group (n = 6) over a 9 cm
2 hair-free area. The treated areas were visually inspected at 1 and 24 h for signs of erythema and/or edema. The skin condition was assessed using the Draize scoring criteria, which rates erythema severity on a scale of 0 to 4:0 for no erythema, 1 for slight erythema (very faint light pink), 2 for moderate erythema (dark pink), 3 for moderate to severe erythema (light red), and 4 for severe erythema (extreme redness). This method provided a standardized assessment of skin irritation [
43].
2.14. Stability Studies
Short-time stability of the selected nanoemulsion (S3) was assessed over three months under refrigeration (2–8 °C) in an amber container. Various factors like phase separation, flocculation, precipitation, drug content (%), pH, transmittance (%), dilution potential, droplet size, PDI, zeta potential and viscosity. The TDL nanoemulgel was stored in glass vials under controlled conditions of 25 ± 0.2 °C and 75 ± 5% RH (Climate chamber, Memmert, Germany) for three months [
44]. Test formulations were taken at various intervals and assessed for appearance, pH, viscosity, and drug content. All experiments were conducted in triplicate, and the results are presented as the mean ± standard deviation (SD).
2.15. Data Analysis
All results were reported as the mean ± SD. Student’s t-test or one-way ANOVA was used to assess statistical significance between groups, with a p-value less than 0.05 considered significant. All data were statistically analyzed with GraphPad Prism 10 (GraphPad Software, Version 10.4.1).
4. Conclusions
The aqueous titration method, guided by a ternary phase diagram, was utilized to develop a TDL nanoemulsion incorporating cinnamon oil as the oil phase and an optimized surfactant–cosurfactant (Smix) ratio (1:0.7) consisting of Cremophor RH40 (surfactant) and Transcutol (cosurfactant). The optimized nanoemulsion (S3) contained 10.1% oil, 55.04% Smix, and 34.86% water, exhibiting a spherical morphology, nano-sized droplets (~92 nm), a neutral zeta potential (0.0 mV), and enhanced steady-state flux (71.85 μg/cm2/h). FTIR analysis confirmed the absence of drug–excipient interactions, while TEM imaging revealed uniformly dispersed vesicles with no agglomeration. To improve skin application, the nanoemulsion was incorporated into a carpool-based gel, which was found to be smooth, uniform, and transparent, making it suitable for transdermal therapy. High ex vivo permeation observed here indicates its potential as an effective TDL carrier system. Pharmacodynamic studies demonstrated that transdermal application of the TDL nanoemulgel effectively mitigated cold-induced vasoconstriction, maintaining blood flow comparable to standard nitroglycerin topical ointment. Pharmacokinetic evaluation revealed significantly higher (p < 0.001) drug absorption by transdermal therapy than by oral nanosuspension delivery. The developed TDL nanoemulgel demonstrates strong potential for transdermal therapy, offering once-daily application and comparable pharmacokinetic and pharmacodynamic effects. These findings highlight its viability as a promising alternative to oral therapy for RP. However, the study has certain limitations, including the use of thermal imaging instead of the more precise laser doppler flowmetry for assessing blood flow and its reliance on a cold-induced rat model, which does not fully capture the complexity of the human condition. Thus, further validation in clinical settings is warranted.
Future studies should involve human subjects, utilize laser doppler imaging, and explore the formulation’s application in other vasoconstrictive conditions, such as acrocyanosis. Evaluating larger sample sizes and non-cold-induced models may further establish its benefits, including faster vasodilation, symptom relief, improved quality of life, and a reduced risk of complications such as tissue necrosis, digital ulcers, gangrene, and functional impairment.